ECM
SEEL

Endurant Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Endurant Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-159
Closed -$3.05M – 81
2021
Q1 		$3.05M Buy
+159
New +$1.86M 0.8% 41

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Endurant Capital Management's SEEL Position: Q2 2021 in Review

Endurant Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2021, closing a stake of 159 shares — an estimated $3.05M sold.

Endurant Capital Management first reported a position in SEEL in Q1 2021 and held it in 1 quarter. The position peaked at $3.05M in Q1 2021. 92 funds tracked by Wall St. Rank hold SEEL as of Q2 2021.

  • Endurant Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Endurant Capital Management sold 159 Seelos Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $3.05M.
  • Endurant Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Endurant Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $3.05M in Q1 2021.
  • 92 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Endurant Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.